Dries Feyen

Cardiovascular Institute of the South — United States

Medicine · Health Sciences

20h-index2.1kcitations59works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tissue Engineering and Regenerative Medicine(18), Electrospun Nanofibers in Biomedical Applications(14), Pluripotent Stem Cells Research(10), Cardiomyopathy and Myosin Studies(10), Cardiac electrophysiology and arrhythmias(8)

Publications59 total

Comparing the Efficacy of Myosin Inhibition Versus Thin Filament Calcium Desensitization for Treatment of Pediatric Restrictive Cardiomyopathy Using a Patient-Derived hiPSC Model
Circulation Genomic and Precision Medicine·2025· 1 citedOpen Access
Abstract Mo097: Inhibiting the Sarcomere Improves Diastolic Dysfunction in Patient-Derived hiPSC-CM Models of Pediatric Restrictive Cardiomyopathy
Circulation Research·2024
Abstract 18778: Patient-Derived Stem Cell Models of Pediatric Restrictive Cardiomyopathy Exhibit Increased Resting Tension and Cardiomyocyte Calcium Sensitivity
Circulation·2023
The circadian clock remains intact, but with dampened hormonal output in heart failure
EBioMedicine·2023· 37 citedOpen Access
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
2023Open Access
A deep learning platform to assess drug proarrhythmia risk
Cell stem cell·2022· 23 citedOpen Access
Abstract 15247: A Novel Patient-Derived Stem Cell Model of Restrictive Cardiomyopathy Exhibits Impaired Cardiomyocyte Relaxation Secondary to Increased Myocardial Calcium Sensitivity
Circulation·2022
Abstract 15594: Decreasing the High Risk of Ponatinib-Induced Cardiovascular Toxicity in Chronic Myeloid Leukemia
Circulation·2022
Transcriptional regulation profiling reveals PPARA-mediated fatty acid oxidation as a novel therapeutic target in phospholamban R14del cardiomyopathy
Research Square (Research Square)·2022· 2 citedOpen Access
Abstract P2109: Elaborating Safety Margins To Predict Drug Proarrhythmia Using Deep Learning And Patient-derived IPSCs.
Circulation Research·2022
Abstract P2113: A Novel Patient-derived Stem Cell Model Of Restrictive Cardiomyopathy Exhibits Impaired Cardiomyocyte Relaxation Secondary To Increased Myocardial Calcium Sensitivity
Circulation Research·2022
Abstract P3105: Improving Cardiovascular Toxicity Of Chronic Myeloid Leukemia Therapy.
Circulation Research·2022
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy
European Heart Journal·2022· 64 citedOpen Access
Abstract LB077: Reengineering ponatinib to minimize cardiovascular toxicity
Cancer Research·2022
Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Cancer Research·2022· 17 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Mark Mercola(26), Joost P. G. Sluijter(24), Pieter A. Doevendans(23), Arne A.N. Bruyneel(13), Ricardo Serrano(13), Michelle M. Vu(11), Prashila Amatya(11), Linda W. van Laake(9), Anna P. Hnatiuk(8), Roberto Gaetani(7), Steven A. J. Chamuleau(7), Ioannis Karakikes(6), Mallesh Pandrala(6), Sanjay V. Malhotra(6), Elisa Messina(5), Arpit Dheeraj(5), Isabel Morgado(5), Volker Wiebking(5), Matthew H. Porteus(5), Ravindra Majeti(5)